ConductScience.org, home

Comparison · NCT00443599-e3369a85

Tight Glycemic Control vs Standard Care: Mortality at 30 Days.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Tight Glycemic Control vs Standard Care: Mortality at 30 Days. Trial comparisons, record NCT00443599-e3369a85. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00443599-e3369a85

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01020.004380.0238wilson
Risk in group 20.01240.005690.0268wilson
Risk difference, group 1 minus group 2-0.00215-0.01770.0129newcombe hybrid score
Risk ratio, group 1 over group 20.8270.2542.69log
Odds ratio, group 1 over group 20.8250.252.72log
Number needed to treat, for one fewer participant with the outcome on Tight Glycemic Control than on Standard Care465from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: standard care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Tight Glycemic Control
Insulin was infused to target a blood glucose concentration of 80-110 mg/dL.~Insulin: Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
5488OG000
Group 2Standard CareInsulin was infused according to the discretion of the treating clinical team.~Usual Care: Participants receive standard Cardiac ICU care without tight blood glucose control.6484OG001

Outcome

Type
SECONDARY
Title
Mortality at 30 Days.
Description
Mortality is assessed at hospital discharge and at 30 days. If the participant is discharged from the hospital prior to 30 days, status is determined by a follow-up phone call to the family.
Time frame
Measured at 30 days.
Population
This outcome was not measured for participants lost to follow-up at 30 days post cardiac surgery.

Source ClinicalTrials.gov

Trial

Title
SPECS: Safe Pediatric Euglycemia in Cardiac Surgery
NCT number
NCT00443599
Phases
NA
Conditions
Heart Defects, Congenital, Hyperglycemia
Interventions
Insulin, Usual Care
Lead sponsor
Boston Children's Hospital
Results first posted
2014-03-10

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00443599-e3369a85